Diluted loss per share considers the impact of potentially dilutive securities. We identified financial instruments that qualify as potential common shares: (i) the share-based options awards described in Note 11 (Stock-based Compensation), (ii) the warrants described in Note 6 (Warrant Liabilities), and (iii) the earnout liabilities described in Note 7 (Earnout Liabilities). Each of these potential common shares is antidilutive since their conversion to common shares would decrease loss per share from continuing operations.

Basic and diluted net income (loss) per share attributable to common stockholders is calculated as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Numerator
Net loss attributable to holders of Common Stock	$	(20,049)	$	(6,652)	$	(138,351)	$	(39,233)


Denominator
Basic and diluted weighted-average shares of Common Stock outstanding	150,594,308		103,206,882		145,794,960		99,949,214




Net loss per share for the period attributable to holders of Common Stock
Basic	$	(0.13)	$	(0.06)	$	(0.95)	$	(0.39)
Diluted	$	(0.13)	$	(0.06)	$	(0.95)	$	(0.39)

Additionally, the following securities outstanding at each period end were not included in the quarter-to-date or year-to-date computation of diluted shares outstanding because the effect would have been anti-dilutive:


	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025
Warrants	49,184,814	49,184,815	49,184,814	49,184,815
Sponsor earnout shares	1,775,962	1,775,962	1,775,962	1,775,962
Stock options	1,092,649	1,995,277	1,092,649	1,995,277
Unvested restricted stock units	2,934,730	3,564,199	2,934,730	3,564,199
Deferred issuance restricted stock units	911,719	385,900	911,719	385,900
Shares convertible from Secured Convertible Notes	15,000,000	25,000,000	15,000,000	25,000,000
Total	70,899,874	81,906,153	70,899,874	81,906,153